Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

70 recalls, newest first

Class II · Moderate risk

MYORISAN (isotretinoin capsules, USP)

Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.

Terminated Labeling / mix-up Akorn, Inc. NDC 61748-302-13 D-0647-2020
Class III · Low risk

Levetiracetam Injection

Labeling: Incorrect or Missing Package Insert - the incorrect package insert version was attached.

Terminated Labeling / mix-up X-Gen Pharmaceuticals Inc. NDC 39822-4000-1 D-0519-2020
Class III · Low risk

Testosterone Cypionate Injection

Labeling:Label Mix-up: Shipper Carton labelled Testosterone Cypionate Injection, USP, 200mg/mL, 1 ml single-dose vials, found to contain shelf cartons labelled as Testosterone Cypionate Injection USP, 200mg/mL, 10 ml multi-dose vials which contain Testosterone Cypionate Injection USP, 200mg/mL,1mL single-does vials

Terminated Labeling / mix-up Arbor Pharmaceuticals Inc. NDC 52536-625-01 D-0167-2020
Class III · Low risk

Sodium Chloride Injection USP 0.9%

Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Terminated Labeling / mix-up Guerbet LLC NDC 0019-1188-27 D-0138-2020
Class II · Moderate risk

Optiray 320

Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Terminated Labeling / mix-up Guerbet LLC NDC 0019-1323-00 D-0137-2020
Class III · Low risk

Zarontin (ethosuximide capsules, USP)

Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.

Terminated Labeling / mix-up Pfizer Inc. NDC 0071-0237-24 D-0002-2020
Class III · Low risk

ethosuximide capsules

Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.

Terminated Labeling / mix-up Pfizer Inc. NDC 59762-2250-2 D-0001-2020
Class I · High risk

Quinacrine Dihydrochloride

Label Mix-Up: Product labeled as Quinacrine Dihydrochloride; however, after testing, identified as Artemisinin.

Terminated Labeling / mix-up Darmerica, LLC NDC 71052-530-05 D-0125-2020
Class II · Moderate risk

Ascorbic Acid Sterile Injection Solution

Labeling: Not Elsewhere Classified; product is labeled as "Non-Corn Source" however the product is from a corn source.

Terminated Labeling / mix-up Atlas Pharmaceuticals, LLC NDC 71591-500-50 D-0144-2020
Class III · Low risk

Lamivudine Tablets

Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.

Terminated Labeling / mix-up American Health Packaging NDC 60687-362-21 D-1847-2019
Class III · Low risk

Simvastatin Tablets

Labeling; Incorrect or Missing Lot and/or Exp Date; some bottles labeled with lot number 05318054B instead of 05318034B

Terminated Labeling / mix-up Aurobindo Pharma USA Inc. NDC 65862-053-99 D-1842-2019
Class I · High risk

Pecgen DMX Cough Suppressant Expectorant

Labeling: Incorrect Instructions; The product has been found to provide incorrect dosage information on its label due to a typographical error. The drug facts label incorrectly states children 6 to under 2 years of age, 1 teaspoonful every 4 hours, not to exceed 4 teaspoonfuls in 24 hours or directed by physician. The label should state children 6 to under 12, 1 teaspoonful every 4 hours, not to exceed 4 teaspoonfuls in 24 hours or as directed by physician. Additionally, the label does not advise consumers to consult a doctor for children under 2 years of age.

Terminated Labeling / mix-up Novis PR, Inc. NDC 52083-630-16 D-1395-2019
Class II · Moderate risk

Amitiza (lubiprostone)

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Terminated Labeling / mix-up Mallinckrodt Pharmaceuticals NDC 64764-240-60 D-1295-2019
Class II · Moderate risk

Amitiza (lubiprostone)

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Terminated Labeling / mix-up Mallinckrodt Pharmaceuticals NDC 64764-080-60 D-1294-2019
Class II · Moderate risk

Articaine DENTAL

Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the printed carton are labeled appropriately as Articadent DENTAL.

Terminated Labeling / mix-up Septodont Inc. NDC 66312-601-16 D-1307-2019
Class III · Low risk

Relpax (eletriptan HBr)

Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg eletriptan, instead of 40mg, on one side of the carton.

Terminated Labeling / mix-up Pfizer Inc. NDC 0049-2340-05 D-1278-2019
Class III · Low risk

Dermoplast Anesthetic PAIN & ITCH

Labeling: Not Elsewhere Classified: Full cases may contain canisters that incorrectly state the net weight is 2.75 oz. rather than the correct net weight of 2.0 oz.

Terminated Labeling / mix-up Advantice Health D-1280-2019

Recalls by year